Evidence map›Paper›PMID 34778040›Full record

ArticleFrontiers in oncology2021

Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study.

György Rokszin, Zoltán Kiss, Gábor Sütő, Péter Kempler, György Jermendy, Ibolya Fábián, Zoltán Szekanecz, Gyula Poór, István Wittmann, Gergő Attila Molnár

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

György RokszinRxTarget Ltd, Szolnok, Hungary.
Zoltán KissSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary.
Gábor SütőSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary.
Péter KemplerDepartment of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
György JermendyBajcsy-Zsilinszky Hospital, Budapest, Hungary.
Ibolya FábiánRxTarget Ltd, Szolnok, Hungary.
Zoltán SzekaneczDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Gyula PoórNational Institute of Rheumatology and Physiotherapy, Budapest, Hungary.
István WittmannSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary.
Gergő Attila MolnárSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, Pécs, Hungary.
University of Pecs · HUBajcsy-Zsilinszky Kórház és Rendelőintézet · HUNational Institute of Oncology · HUSemmelweis University · HUUniversity of Debrecen · HUUniversity of Veterinary Medicine · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn diabetes mellitus, during the last years, cancer became of equivalent importance as a cardiovascular disease in terms of mortality. In an earlier study, we have analyzed data of the National Health Insurance Fund (NHIF) of Hungary with regards all patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) PATIENTS AND

methodsAll patients starting an SGLT2i or a DPP-4i between 2014 and 2017 in Hungary were included; the two groups (SGLT2i

resultsWe found a lower risk of urinary tract [HR 0.50 (95% CI: 0.32-0.79) p = 0.0027] and hematological malignancies [HR 0.50 (95% CI: 0.28-0.88) p = 0.0174] in patients treated with SGLT2i

conclusionsUrinary tract and hematological malignancies were less frequent in patients treated with SGLT2i

Indexed as

antidiabetic treatmentcancerdiabetes mellitus type 2dipeptidyl peptidase (DPP)-4 inhibitorssodium-glucose co-transporter 2 (SGLT 2) inhibitors

Identifiers

PMID34778040
PMCPMC8581296
OpenAlexW3208371788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.